These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12740004)

  • 21. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials.
    Black HR
    Clin Cornerstone; 2004; 6(4):53-66. PubMed ID: 15850766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
    Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
    Barzilay JI; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Black HR; Cushman WC; Ford CE; Margolis KL; Moloo J; Oparil S; Piller LB; Simmons DL; Sweeney ME; Whelton PK; Wong ND; Wright JT;
    Circ Cardiovasc Qual Outcomes; 2012 Mar; 5(2):153-62. PubMed ID: 22396585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
    Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
    J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
    Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
    Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
    Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations for the management of special populations: racial and ethnic populations.
    Ferdinand KC
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):50S-54S. PubMed ID: 14625162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Piller LB; Ford CE; Davis BR; Nwachuku C; Black HR; Oparil S; Retta TM; Probstfield JL;
    J Clin Hypertens (Greenwich); 2006 Sep; 8(9):649-56; quiz 657-8. PubMed ID: 16957427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Siragy HM
    Curr Hypertens Rep; 2003 Aug; 5(4):293-4. PubMed ID: 12844462
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Arnett DK; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Miller MB; Black H; Eckfeldt JH
    Circulation; 2005 Jun; 111(25):3374-83. PubMed ID: 15967849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Grimm RH; Margolis KL; Papademetriou V; Cushman WC; Ford CE; Bettencourt J; Alderman MH; Basile JN; Black HR; DeQuattro V; Eckfeldt J; Hawkins CM; Perry HM; Proschan M
    Hypertension; 2001 Jan; 37(1):19-27. PubMed ID: 11208751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.
    Geraci TS; Geraci SA
    J Cardiovasc Nurs; 2003; 18(5):389-95. PubMed ID: 14680343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treating hypertension is more important than the choice of agent; results from the largest clinical trial until now].
    de Leeuw PW; Birkenhäger WH
    Ned Tijdschr Geneeskd; 2003 Apr; 147(15):685-9. PubMed ID: 12722529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study.
    Punzi HA; Punzi CF; ;
    Curr Hypertens Rep; 2004 Apr; 6(2):106-10. PubMed ID: 15010012
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.